| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
TNG-0746132 is not a biologically active drug itself but is used as a chemical intermediate for the synthesis of compounds with anticancer activity. The final anticancer agents that are synthesized from TNG-0746132 likely target proteins involved in cancer cell proliferation and survival, such as kinases or other regulatory proteins. The specific molecular target of the final compound is not detailed in the literature, but it is designed for oncology research.
|
|---|---|
| ln Vitro |
The in vitro activity of TNG-0746132 itself is not described, as it is a synthetic intermediate. However, the final compound synthesized from TNG-0746132 has anticancer activity, implying that it can inhibit the growth of cancer cells in vitro. The intermediate is used to prepare the final biologically active molecule. Typically, the final compound would be assessed in cytotoxicity assays against a panel of cancer cell lines (e.g., MCF-7, A549, HCT-116) to determine its half-maximal inhibitory concentration (IC50).
|
| ln Vivo |
TNG-0746132 is not a drug and does not have its own in vivo activity. The final compound synthesized from TNG-0746132 is expected to have anticancer activity in vivo. Such a compound would be assessed in animal models of cancer, such as mouse xenografts. The intermediate is a chemical tool for the synthesis of these anticancer candidates. The product is a starting material for further drug discovery.
|
| Enzyme Assay |
TNG-0746132 is a chemical compound, and there is no standard cell-free biochemical assay for its own biological activity, as it is not a drug. Its primary characterization is through analytical chemistry methods such as High-Performance Liquid Chromatography (HPLC) and mass spectrometry (MS) to assess its purity and identity. The compound is stable as a powder at -20degC for up to 3 years and is soluble in DMSO (33.33 mg/mL, 65.94 mM). The IUPAC name is 2-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-7-(4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-5H-pyrrolo[3,2-d]pyrimidine.
|
| Cell Assay |
There are no standard cell-based assays for TNG-0746132 itself, as it is not a biologically active agent. The final compound synthesized using TNG-0746132 would be assessed in cellular assays. A typical cytotoxic assay would involve treating cancer cell lines with various concentrations of the final compound for 48-72 hours, followed by an MTT or CellTiter-Glo viability assay. IC50 values would be calculated. Apoptosis and cell cycle effects would be characterized by flow cytometry. TNG-0746132 is only a synthetic intermediate.
|
| Animal Protocol |
TNG-0746132 is not used directly in animal experiments; it is a synthetic intermediate. The final anticancer compound would be tested in mouse xenograft models. For example, immunodeficient mice are implanted with cancer cells (e.g., HCT-116 or A549) subcutaneously. Once tumors reach ~100-200 mm3, mice are treated with the final compound at various doses (e.g., 10-50 mg/kg) via oral gavage or intraperitoneal (IP) injection. Tumor volume and body weight are measured regularly. The final compound's efficacy is determined by the reduction in tumor growth compared to the vehicle control. TNG-0746132 itself is not administered.
|
| ADME/Pharmacokinetics |
TNG-0746132 has a molecular weight of 505.49 and a molecular formula of C26H22F3N7O. It is a solid powder with a purity of ≥98%. It is soluble in DMSO (33.33 mg/mL). The compound should be stored as a powder at -20degC for long-term stability (up to 3 years), and once dissolved, solutions can be stored at -80degC for up to 1 year. The pharmacokinetic properties (half-life, bioavailability) are not reported, as it is not a final drug candidate.
|
| Toxicity/Toxicokinetics |
Toxicity data for TNG-0746132 is not available, as it is not intended for biological testing or therapeutic use. It is a chemical intermediate used for the synthesis of other compounds. Standard chemical safety precautions should be followed when handling this compound, including the use of personal protective equipment (gloves, lab coat, safety goggles) and working in a well-ventilated area (e.g., fume hood). Inhalation, ingestion, and skin contact should be avoided.
|
| References |
[1]. Throner Scott, et al. Preparation of pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer. World Intellectual Property Organization, WO2022174184 A1. 2022-08-18.
|
| Additional Infomation |
TNG-0746132 (CAS 2821749-57-7) is a synthetic intermediate used in the preparation of compounds with anticancer activity. It contains a trifluoromethyl group, which is often incorporated into drug molecules to improve metabolic stability, bioavailability, and binding affinity. The compound is for research and development use only and is not for human therapeutic use. It is strictly a chemical building block for drug discovery. More detailed information may be available from the patent literature, and researchers are directed to reference [1] (Throner Scott, et al.) for further details.
|
| Molecular Formula |
C26H22F3N7O
|
|---|---|
| Molecular Weight |
505.49
|
| Exact Mass |
505.183
|
| CAS # |
2821749-57-7
|
| PubChem CID |
164881289
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.8
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
37
|
| Complexity |
778
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN1C=C(N=C1C2=CC=C(C=C2)CC3=CNC4=CN=C(N=C34)C5=C(N=CN=C5OC)C6CC6)C(F)(F)F
|
| InChi Key |
ONJHDRGRJAZAHT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C26H22F3N7O/c1-36-12-19(26(27,28)29)34-24(36)16-5-3-14(4-6-16)9-17-10-30-18-11-31-23(35-21(17)18)20-22(15-7-8-15)32-13-33-25(20)37-2/h3-6,10-13,15,30H,7-9H2,1-2H3
|
| Chemical Name |
2-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-7-[[4-[1-methyl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]-5H-pyrrolo[3,2-d]pyrimidine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9783 mL | 9.8914 mL | 19.7828 mL | |
| 5 mM | 0.3957 mL | 1.9783 mL | 3.9566 mL | |
| 10 mM | 0.1978 mL | 0.9891 mL | 1.9783 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
